Parkinson’s News Today is bringing back its “30 Days of Parkinson’s” initiative for the second year during Parkinson’s Disease Awareness Month in April. This project is aimed at raising awareness by highlighting different voices within the Parkinson’s community. Every day in April, we will feature a story from someone…
A real-time, home-monitoring system allowed for remote detection and management of orthostatic hypotension — a sudden drop in blood pressure when changing positions — in people with Parkinson’s disease during the COVID-19 pandemic, a pilot study shows. Notably, the eight patients involved reported these episodes profoundly affect daily life…
Some people with Parkinson’s disease have a characteristic genetic signature in a type of immune cell called memory T-cells, a new study suggests. “Parkinson’s disease is not usually seen as an autoimmune disease, but all of our work points toward T cells having a role in the disease,” Cecilia…
A form of the alpha-synuclein protein that can build up in the skin could help distinguish Parkinson’s disease from other neurodegenerative disorders, a study has found. Skin biopsy samples taken from Parkinson’s disease patients all showed a buildup of phosphorylated alpha-synuclein (p-syn), which is alpha-synuclein with an added phosphate…
A positron emission tomography (PET) tracer for the alpha-synuclein protein, whose damaging clumps mark Parkinson’s, captured its toxic aggregates in a living brain for a first time — instead of in post-mortem tissue as is done to date, scientists reported. The tracer, called ACI-12589, is a diagnostic tool designed to…
Combining a 12-week program of virtual reality (VR) training and motor imagery exercises with standard physical therapy (PT) significantly lessened motor symptoms — including tremors, slow movements (bradykinesia), and postural instability — among people with Parkinson’s disease, according to a recent study. “To the best of our knowledge, this…
A Phase 4 clinical trial called OCEAN is testing whether Ongentys (opicapone), an add-on therapy for “off” periods, can ease pain in people with Parkinson’s disease. The placebo-controlled trial (NCT04986982), which opened in February 2021, is evaluating Ongentys’ effectiveness in up to 140 adults with idiopathic (non-familial)…
JOGO-Gx, a device powered by an artificial intelligence-driven mobile app and wearable sensors, has shown early positive signs as a method to lessen motor symptoms in people with Parkinson’s disease. According to JOGO Health, the company that owns JOGO-Gx, using the device at least twice a week led…
Early results from the Phase 2 clinical trial of oral SAGE-718 showed the investigative therapy’s use was associated with cognitive gains in people with mild impairment due to Parkinson’s disease. These findings were presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s…
Anavex 2-73 (blarcamesine), an investigational oral therapy for Parkinson’s disease dementia, led to clinically meaningful improvements within all four MDS-UPDRS assessments for patients treated daily at high dose, according to new data from a completed Phase 2 trial. These benefits, in both motor and non-motor Parkinson’s…
Get regular updates to your inbox.
